Announcements Trials
Browse Landscape

Phase

Phase 1 25Phase 1/2 13Phase 2 12Phase 3 4

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 1Lymphoma 1

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × romidepsin × Lymphoid × Clear all
NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Celgene

Phase 3 Active not recruiting
93 enrolled 19 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell

NCT01796002 2023-01-10

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

The Lymphoma Academic Research Organisation

Phase 3 Completed
421 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03355768 2018-12-19

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Columbia University

Phase 3 Withdrawn
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Takeda

Phase 3 Completed
271 enrolled 25 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡